Adrian Bogdan Țigu

Dr. Adrian Bogdan Țigu

Department of Personalized Medicine and Rare Diseases, MEDFUTURE–Institute for Biomedical Research, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Cluj, Romania
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
AZAlina-Andreea Zimta
Alina-Andreea Zimta
Adrian Bogdan ȚiguAdrian Bogdan Țigu
Adrian Bogdan Țigu
CBCornelia Braicu
Cornelia Braicu
CSCristina Stefan
Cristina Stefan
CICalin Ionescu
Calin Ionescu
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
The small nucleolar RNA host geness (SNHG) consist of a group of long non-coding RNAs, which are reported in many studies as being overexpressed in various cancers. With very few exceptions, the SNHGs (SNHG1, SNHG3, SNHG5, SNHG6, SNHG7, SNHG12, SNHG15, SNHG16, SNHG20) are recognized as inducing increased proliferation, cell cycle progression, invasion and metastasis of cancer cells which makes this class of transcripts a viable biomarker for cancer development and aggressiveness. Through our literature research , we also found silencing of SNHGs through small interfering RNAs or short hairpin RNAs is very effective in both in vitro and in vivo experiments by lowering solid cancers aggressiveness. The knock down of SNHG as a new cancer therapeutic option should be investigated more in the future.

21 October 2019 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
Sanda BocaSanda Boca
Sanda Boca
DGDiana Gulei
Diana Gulei
AZAlina-Andreea Zimta
Alina-Andreea Zimta
AOAnca Onaciu
Anca Onaciu
LMLorand Magdo
Lorand Magdo
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe

Verified
Journal Article
Open access
PDF file
AZAlina-Andreea Zimta
Alina-Andreea Zimta
Adrian Bogdan ȚiguAdrian Bogdan Țigu
Adrian Bogdan Țigu
MMMaximilian Vlad Muntean
Maximilian Vlad Muntean
Diana M CenariuDiana M Cenariu
Diana M Cenariu
Ondrej SlabyOndrej Slaby
Ondrej Slaby
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
Worldwide, breast cancer (BC) is the most common malignancy in women, in regard to incidence and mortality. In recent years, the negative role of obesity during BC development and progression has been made abundantly clear in several studies. However, the distribution of body fat may be more important to analyze than the overall body weight. In our review of literature, we reported some key findings regarding the role of obesity in BC development, but focused more on central adiposity. Firstly, the adipose microenvironment in obese people bears many similarities with the tumor microenvironment, in respect to associated cellular composition, chronic low-grade inflammation, and high ratio of reactive oxygen species to antioxidants. Secondly, the adipose tissue functions as an endocrine organ, which in obese people produces a high level of tumor-promoting hormones, such as leptin and estrogen, and a low level of the tumor suppressor hormone, adiponectin. As follows, in BC this leads to the activation of oncogenic signaling pathways: NFκB, JAK, STAT3, AKT. Moreover, overall obesity, but especially central obesity, promotes a systemic and local low grade chronic inflammation that further stimulates the increase of tumor-promoting oxidative stress. Lastly, there is a constant exchange of information between BC cells and adipocytes, mediated especially by extracellular vesicles, and which changes the transcription profile of both cell types to an oncogenic one with the help of regulatory non-coding RNAs.

1 May 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
CBCornelia Braicu
Cornelia Braicu
OZOana Zanoaga
Oana Zanoaga
AZAlina-Andreea Zimta
Alina-Andreea Zimta
Adrian Bogdan ȚiguAdrian Bogdan Țigu
Adrian Bogdan Țigu
KKKaitlyn L. Kilpatrick
Kaitlyn L. Kilpatrick
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe

Verified
Journal Article
Open access
PDF file
Liviuta BudisanLiviuta Budisan
Liviuta Budisan
Diana GuleiDiana Gulei
Diana Gulei
Ancuta JurjAncuta Jurj
Ancuta Jurj
Cornelia BraicuCornelia Braicu
Cornelia Braicu
OZOana Zanoaga
Oana Zanoaga
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
Background: Phytochemicals are natural compounds synthesized as secondary metabolites in plants and represent an important source of molecules with therapeutic applications. Attention is accorded to their potential in anti-cancer therapies as single agents or adjuvant treatment. Herby, we evaluated the in vitro effects of a panel of natural compounds with focus on caffeic acid phenethyl ester (CAPE) and Kaempferol for the treatment of human colon cancer. Methods: We exposed two human colon cancer cell lines, RKO and HCT-116, followed by functional examination of cell viability, cell proliferation and invasion, cell cycle, apoptosis, and autophagy. Modifications in gene expression were investigated through microarray and detection of existing mutations and finding of new ones was done with the help of Next Generation Sequencing (NGS). Results: Both CAPE and Kaempferol inhibit cell proliferation, motility and invasion, and stimulate apoptosis and autophagy, concomitant with modifications in coding and noncoding genes’ expression. Moreover, there are pathogenic mutations that are no longer found upon treatment with CAPE and Kaempferol. Conclusions: Our findings indicate that CAPE and Kaempferol have the ability to negatively influence the development and advancement of colon cancer in vitro by specifically altering the cells at the molecular level; this activity can be exploited in possible adjuvant therapies once the optimal dose concentration with minimal side effects but with cancer inhibitory activity is set in vivo.

31 October 2019 in Molecules
Verified
Journal Article
Open access
PDF file
MPMarcel Parvu
Marcel Parvu
AMAugustin C. Moţ
Augustin C. Moţ
Alina Elena PârvuAlina Elena Pârvu
Alina Elena Pârvu
CMCristina Mircea
Cristina Mircea
LSLeander Stoeber
Leander Stoeber
Adrian Bogdan ȚiguAdrian Bogdan Țigu
Adrian Bogdan Țigu
Onychomycosis is a major health problem due to its chronicity and resistance to therapy. Because some cases associate paronychia, any therapy must target the fungus and the inflammation. Medicinal plants represent an alternative for onychomycosis control. In the present work the antifungal and antioxidant activities of Alium sativum extract against Meyerozyma guilliermondii (Wick.) Kurtzman & M. Suzuki and Rhodotorula mucilaginosa (A. Jörg.) F.C. Harrison, isolated for the first time from a toenail onychomycosis case, were investigated. The fungal species were confirmed by DNA molecular analysis. A. sativum minimum inhibitory concentration (MIC) and ultrastructural effects were examined. At the MIC concentration (120 mg/mL) the micrographs indicated severe structural alterations with cell death. The antioxidant properties of the A. sativum extract were evaluated is a rat turpentine oil induced inflammation, and compared to an anti-inflammatory drug, diclofenac, and the main compound from the extract, allicin. A. sativum reduced serum total oxidative status, malondialdehyde and nitric oxide production, and increased total thiols. The effects were comparable to those of allicin and diclofenac. In conclusion, the garlic extract had antifungal effects against M. guilliermondii and R. mucilaginosa, and antioxidant effect in turpentine-induced inflammation. Together, the antifungal and antioxidant activities support that A. sativum is a potential alternative treatment in onychomycosis.